Accept Cookies?
Provided by OpenGlobal E-commerce

Please wait while your page loads ...

 

Scientific News

FARA funds research progress

In this section, you will find the most recent FA research publications, many of which are funded by FARA, as well as information on upcoming conferences and symposiums. You can search for articles by date using the archive box in the right hand column. To locate FARA Funded or Supported Research, click the hyperlink in the right hand column. You may also search for specific content using key words or phrases in the search button at the top right of your screen. Please be sure to visit other key research sections of our website for information on FARA’s Grant Program and the Treatment Pipeline.


Dysarthria in Friedreich's Ataxia: A Perceptual Analysis

he University of Queensland, Brisbane, Qld., bBruce Lefroy Centre, Murdoch Childrens Research Institute, Royal Children’s Hospital, Melbourne, Vic., and cRoyal Children’s Hospital, Brisbane, Qld., Australia 

Dysarthria in Friedreich's Ataxia: A Perceptual Analysis

Understanding the molecular mechanisms of Friedreich Ataxia to develop therapeutic approaches

Friedreich's ataxia (FRDA) is a neurodegenerative disease caused by reduced expression of the mitochondrial protein frataxin. The physiopathological consequences of frataxin deficiency are a severe disruption of iron–sulfur cluster biosynthesis, mitochondrial iron overload coupled to cellular iron dysregulation and an increased sensitivity to oxidative stress. Frataxin is a highly conserved protein, which has been suggested to participate in a variety of different roles associated with cellular iron homeostasis.

Understanding the molecular mechanisms of Friedreich Ataxia to develop therapeutic approaches

Therapeutic use of coenzyme Q(10) and coenzyme Q(10)-related compounds and formulations

What the reader will gain: This review covers the most relevant aspects related with the therapeutic use of CoQ10, including existing formulations and their effects on its bioavailability.

Take home message: CoQ10 does not cause serious adverse effects in humans and new formulations have been developed that increase CoQ10 absorption. Oral CoQ10 is a viable antioxidant strategy in many diseases, providing a significant to mild symptomatic benefit. Idebenone and MitoQ are promising substitutive CoQ10-related drugs which are well tolerated and safe.

Read More: Therapeutic use of coenzyme Q(10) and coenzyme Q(10)-related compounds and formulations
Page 202 of 227

SHARE

FacebookTwitterLinkedInYoutube

 

Archived in
  Scientific News


 

 

Tagged in
FARA Scientific News


Site Map     Privacy Policy      Service Terms      Contact      Charity Navigator